High prevalence of co-factor independent anticardiolipin antibodies in malaria exposed individuals.
Anticardiolipin antibodies (aCL) were investigated in 137 individuals chronically exposed to malaria and living in Africa and Asia. They belonged to several groups according to parasite (Plasmodium falciparum or vivax) and clinical manifestations (i.e. asymptomatic parasite carriers, acute uncomplicated attack or severe malaria episodes). aCL were measured in an enzyme immunoassay (ELISA) performed in the presence of either goat serum (aCLs) or gelatin (aCLg). In a group of 53 patients with autoimmune manifestations (i.e. antiphospholipid syndrome and/or lupus), detection of IgG but not IgM aCL was markedly reduced in the presence of gelatin. In malaria donors, high prevalence of serum co-factor-independent IgG and IgM were detected, and the presence of goat serum in the assay consistently decreased their detection. aCLg levels were found to be related to the clinical/endemic status of donors. IgG aCLg were found to be higher in asymptomatic P. falciparum carriers than in patients with uncomplicated acute or cerebral malaria. IgM aCLg were higher in the cerebral malaria group than in groups with uncomplicated acute malaria patients or asymptomatic individuals. Data suggest that using a serum co-factor independent, sensitive ELISA, aCL are commonly detected during malarial infections and related to malarial infection status.
Consigny
P H
PH
Laboratoire de Parasitologie, UPRES-3234, Faculté de Médecine-Pharmacie, Rouen, France.
Cauquelin
B
B
Agnamey
P
P
Comby
E
E
Brasseur
P
P
Ballet
J J
JJ
Roussilhon
C
C
D000293:Adolescent; D000328:Adult; D000349:Africa / Q000453:epidemiology; D017153:Antibodies, Anticardiolipin / Q000276:immunology*; D016736:Antiphospholipid Syndrome / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D001208:Asia / Q000453:epidemiology; D015551:Autoimmunity; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D016778:Malaria, Falciparum / Q000150:complications / Q000453:epidemiology / Q000276:immunology*; D016780:Malaria, Vivax / Q000150:complications / Q000453:epidemiology / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015995:Prevalence
D017153:Antibodies, Anticardiolipin